Fate Therapeutics Inc (FATE)
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
FATE SEC Filing Email Alerts Service
| Company Name: |
Fate Therapeutics Inc |
| Website: |
www.fatetherapeutics.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding FATE: |
20 |
| Total Market Value Held by ETFs: |
$79.52M |
| Total Market Capitalization: |
$530.00M |
| % of Market Cap. Held by ETFs: |
15.00% |
|
|
April 19, 2024 • 8:01 AM Eastern
Hold (2.43 out of 4)
100th percentile
|
|
Free FATE Email Alerts:
